Cyted Health secures USD 44 million Series B led by EQT Life Sciences to advance early detection in gastrointestinal disease

Cyted Health secures USD 44 million Series B led by EQT Life Sciences to advance early detection in gastrointestinal disease

(IN BRIEF) Cyted Health has raised USD 44 million in Series B financing led by EQT Life Sciences with participation from Advent Life Sciences, the British Business Bank, Morningside, BGF, and HCA Healthcare. The funds will accelerate Cyted’s commercial rollout in the US, support its established partnerships in the UK’s NHS, and enable expansion of its molecular diagnostics portfolio. Cyted’s EndoSign® device and biomarker testing platform have already completed over 35,000 tests with strong evidence of patient acceptance and clinical impact. CEO Marcel Gehrung highlighted the investment as a critical step in scaling life-saving diagnostics, while EQT’s Bruno Holthof noted Cyted’s potential to redefine global standards in GI disease detection.

(PRESS RELEASE) AMSTERDAM, 2-Sep-2025 — /EuropaWire/ — EQT Life Sciences has confirmed a major investment into Cyted Health, a fast-growing gastrointestinal diagnostics company, as part of a USD 44 million Series B round. The financing was co-led by Advent Life Sciences and the British Business Bank (formerly British Patient Capital), with existing supporters Morningside and BGF also contributing. The round additionally benefits from a non-dilutive partnership with HCA Healthcare.

The new capital will fuel Cyted’s commercial scale-up in the United States, broaden its portfolio of molecular diagnostics, and reinforce its progress in the UK market, where it already has a strong clinical footprint. At the heart of Cyted’s platform is EndoSign®, an FDA-cleared device designed for the non-invasive collection of esophageal cells, paired with advanced biomarker testing for the early identification of esophageal disease.

Cyted has already worked extensively with the UK National Health Service, completing more than 35,000 procedures and producing a body of peer-reviewed evidence confirming both patient acceptability and measurable clinical outcomes.

Cyted’s CEO and Co-founder, Marcel Gehrung, described the funding as a turning point: “This financing strengthens our ability to detect esophageal disease at an earlier stage and bring our innovations to more patients. It gives us the platform to grow our presence in the US and to continue to expand our diagnostic pipeline with technologies that can save lives.”

Bruno Holthof, Partner at EQT Life Sciences, added: “Cyted stands out as a company capable of transforming the diagnostic pathway for upper gastrointestinal disease. Its combination of minimally invasive sampling and advanced biomarker discovery offers a compelling answer to a large unmet need, and we are pleased to be backing its next stage of growth.”

Cyted was founded by Cambridge University researchers and is pioneering new methods of cell collection and biomarker analysis to detect precancerous, cancerous, and inflammatory esophageal conditions. Alongside the financing, the company has strengthened its governance with a Clinical Advisory Board of leading gastroenterologists and oncologists who will guide its expansion strategy and diagnostic development, particularly in the US.

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.

More information: https://eqtgroup.com/private-capital/eqt-life-sciences

About Cyted Health

Cyted Health is a gastrointestinal molecular diagnostics company dedicated to improving early detection and prevention of esophageal adenocarcinoma through innovative, minimally invasive diagnostics. The company has built a robust portfolio of peer-reviewed publications, conducted over 35,000 tests using its diagnostic platform, and is widely used across the National Health Service in the UK. Cyted Health is actively expanding its presence in the U.S. to bring its technology to more patients in need.

Website: www.cytedhealth.com

Media Contact:

EQT Press Office
press@eqtpartners.com

SOURCE: EQT